» Articles » PMID: 20837496

Infections in Polymyositis and Dermatomyositis: Analysis of 192 Cases

Overview
Specialty Rheumatology
Date 2010 Sep 15
PMID 20837496
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To estimate the incidence, characteristics and predictors of infections in patients with PM and DM.

Methods: The medical records of 192 PM/DM patients followed up in a tertiary teaching medical centre from 1999 to 2008 were retrospectively reviewed.

Results: Seventy-six episodes of major infection, defined as infections requiring>1 week of treatment with anti-microbial agents, occurred in 53 (27.6%) patients, and 15 (7.8%) patients had two or more episodes. The incidence rate of major infections was 11.1 episodes per 100 patient-years in PM/DM patients. Aspiration pneumonia [n (%)=16 (21.1)] was the leading cause of major infections, followed by opportunistic infection [n (%)=14 (18.4)]. A variety of pathogens were isolated, mainly including Staphylococcus aureus, Klebsiella, Escherichia coli, Salmonella and Mycobacterium. Overall patient survival rates were 85.0% at 1 year, 78.0% at 5 years and 78.0% at 10 years. However, after one episode of major infection, survival rates decreased to 84.7% at 30 days and 68.3% at 1 year. Multivariate analysis indicated that independent predictors of major infection were age>45 years at PM/DM onset [odds ratio (OR) 5.26; 95% CI 2.01, 13.77; P=0.001], presence of arthritis/arthalgia (OR 2.59; 95% CI 1.12, 6.02; P=0.027), co-present interstitial lung disease (OR 7.24; 95% CI 2.67, 19.65; P<0.001), current use of AZA (OR 6.07; 95% CI 2.39, 15.42; P<0.001) or IVIG (OR 6.33; 95% CI 1.50, 26.77; P=0.012).

Conclusions: This study underlines the high frequency of major infections in PM/DM, which is significantly detrimental to patient survival rates. Close follow-up of PM/DM patients with risk factors for developing major infections is mandatory.

Citing Articles

Predictive risk factors for one-year mortality in idiopathic inflammatory myopathy patients with interstitial lung disease: A retrospective, single-center cohort study.

Jiang M, Wen X, Xia S, Guo Y, Bai Y Arch Rheumatol. 2024; 39(2):213-220.

PMID: 38933718 PMC: 11196236. DOI: 10.46497/ArchRheumatol.2024.10418.


Prognostic factors of fungal infection in anti-melanoma differentiation-associated gene 5 antibody-positive associated interstitial lung disease.

Zhou W, Chen H, Ji T, Chen R, Xu Q, Chen L Clin Rheumatol. 2024; 43(4):1381-1392.

PMID: 38345696 DOI: 10.1007/s10067-024-06899-3.


Burkholderia-associated polymyositis.

Kumar S, Kumar N, Panda P, Jandrasupalli K BMJ Case Rep. 2024; 17(1).

PMID: 38232996 PMC: 10806993. DOI: 10.1136/bcr-2023-255782.


Polymyositis/dermatomyositis readmissions: analysis of the nationwide readmission database.

Idolor O, Edigin E, Hino C, He E, Rao J, Ugoh A Clin Rheumatol. 2023; 42(10):2833-2839.

PMID: 37407906 DOI: 10.1007/s10067-023-06690-w.


Risk of Early Infection in Idiopathic Inflammatory Myopathies: Cluster Analysis Based on Clinical Features and Biomarkers.

Cheng L, Li Y, Wu Y, Luo Y, Zhou Y, Liao Z Inflammation. 2023; 46(3):1036-1046.

PMID: 36781687 DOI: 10.1007/s10753-023-01790-w.